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Abstract 
 
Background: End stage renal disease (ESRD) is a growing public health problem in 
Canada and it disproportionately affects Aboriginal people. Diabetes is the most 
common reported cause of ESRD.   
Objectives and methods: To determine whether there are significant disparities in the 
risk of ESRD and mortality without ESRD between diabetic First Nations (FN) and 
other Saskatchewan (OSK) people; to build and validate diabetic ESRD dynamic 
models. This is a population study of diabetes, utilizing data drawn from the 
Saskatchewan Ministry of Health administrative databases from 1980 to 2005. 
Competing risks survival analysis was used, including a Cox cause-specific model, 
Weibull proportional hazards (PH) model and piece-wise exponential PH hazards 
model. System Dynamics modeling (SDM) and agent-based modeling (ABM) methods 
were used to build dynamic models of diabetic patients’ progression to ESRD. 
Results: There were a total of 90,429 diabetic people in the study cohort, from 1980 to 
2005. Among them, 8,254 (9%) of them were FN people. The average age at diabetes 
diagnosis for FN was 47.2 (SD=14) years old while for OSK, it was 61.6 (SD=15.3) 
years old (P-value<0.0001). After adjusting for sex and age at diabetes diagnosis, the 
risk of developing ESRD was 2.97 times higher for FN compared to OSK (95% CI: 
2.51-3.54; P-value<0.0001). FN had lower risk of death than OSK before adjusting for 
age and sex difference. After adjusting for diabetes diagnosis age, sex, interaction 
between age and sex and interaction between age and ethnicity, FN had higher risk of 
death than OSK given the same sex and diabetes diagnosis age (younger than 81 years 
old). Using the same hazard rate estimations from competing risks survival analysis, 
the ABM model demonstrated a better match between historical data and model 
predicted data compared to the SD model. 
Conclusion: A much younger age of diabetes diagnosis among FN compared to OSK 
likely contributes to higher rates of ESRD because of a differential mortality effect – 
FN with diabetes are more likely to live long enough to develop ESRD. 
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Chapter 1 Introduction 
End stage renal disease (ESRD) occurs when the kidneys can no longer function 
adequately for an individual’s daily life. ESRD is considered the last stage of chronic 
kidney disease (CKD), in which only approximately 10% of kidney function remains 
(1). Patients with ESRD need medical treatment to survive, such as dialysis or a kidney 
transplant. ESRD is a growing public health problem in Canada. It was estimated that 
almost 38,000 people were being treated for ESRD by the end of 2009 (2). Diabetes is   
the most common cause of ESRD, accounting for 53.8% of incident cases in 2009, up 
from 26.9% in 1996 (2, 3).   
ESRD disproportionately affects Aboriginal people in Canada (4-6). For example, 
Young et al. (4) found that between 1981 and 1986, the age-standardized incidence of 
ESRD among Canadian Aboriginal people was more than 2.5 times higher than that 
found in the general population. Moreover, Dyck et al. (6) found that from 1980 to 2005 
in Saskatchewan, First Nations (FN) people had higher rates of diabetes-related ESRD 
than other Saskatchewan (OSK) people. The reasons for the greater incidence of 
diabetic ESRD among Aboriginal people with diabetes compared to other Canadians 
with diabetes is currently unclear, but it may result from increased onset rates of 
diabetic glomerulosclerosis, which may result in ESRD (7), higher rates of kidney 
function loss after onset of CKD (CKD) (7), increased survival during later stages of 
CKD (7), poorer glycemic control and reduced access to treatment that helps to slow 
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the progression of CKD (7, 8). In this study, we examined whether there are differences 
in the risks of developing ESRD and death without ESRD between First Nations (FN) 
and other Saskatchewan people (OSK) using competing risks survival analysis. 
Estimations of simultaneous risks of ESRD and death without ESRD will help to 
understand ethnic differences in the rates of ESRD. A better understanding of 
ethnicity-related differences in the risks of these two events would potentially help to 
inform research and interventions that are aimed at reducing disparities in the ESRD 
incidence between First Nations people and other Canadians, and it could be used to 
predict future renal replacement requirements and costs (9).  
In recent years, public health is starting to use computational modeling and 
simulation experiments to assist stakeholders and policy makers to better understand 
the health care system’s structure and interactions among components, to project 
possible future burden of disease outcomes and expenditures, to evaluate health care 
goals and planning strategies both in the short term and the long term, and to understand 
whether there are any conflicts among goals and then to make robust policy (10-15). In 
this thesis, both System Dynamics modeling (SDM) and agent-based modeling (ABM) 
will be used to build diabetic ESRD models and validate these models by comparing 
historical data with model-predicted data.  
The thesis will be divided into the following sections: literature review, including 
the epidemiology of diabetes, epidemiology of CKD, and the use of SDM and ABM for 
public health research; rationale; study objectives; methodology; results; discussion; 
and conclusions.   
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Chapter 2 Literature 
2.1 Nomenclature 
We will use similar terminology described by Young about indigenous populations 
in this thesis (16): “The term Native American encompasses North American Indians, 
Eskimos (Inuit) and Aleut … In Canada, the term Native continues to be used by some 
Native Organizations, although Aboriginal seems to be preferred. Three aboriginal 
groups are recognized in Canada: Indians, Inuit and Métis. The term Indian is slowly 
being replaced by First Nation … The term Métis is used only in Canada, and refers to 
a distinct cultural group that originated form mixed Indian-White marriages in the early 
settlement of the Canadian West.” 
Throughout this thesis, Aboriginal will be used to refer to all North American 
Indigenous People including people of Indian, Inuit and Métis heritage, as well as 
non-Indigenous registered Indians. First Nation will be used to refer to the registered 
indigenous population in Canada. 
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2.2 Epidemiology of diabetes 
2.2.1 Introduction 
Diabetes mellitus (DM) is a chronic disease caused by insufficiencies in insulin, 
compromised action of insulin or some combination of the two. The World Health 
Organization (17) classifies DM into three types: type 1 diabetes (T1DM), type 2 
diabetes (T2DM) and gestational diabetes mellitus (GDM). Diabetes disproportionally 
affects some ethnic groups, such as Aboriginal, African-American, and Hispanic 
people (18).  
Diabetes causes many chronic complications, such as cardiovascular disease, eye 
disease, and renal failure. In 2005, almost 1.1 million people died from diabetes, with 
80% of deaths occurring in low- and middle-income countries (18). According to the 
International Diabetes Federation (19), in 2010, almost 4 million deaths across the 
world could be attributed to diabetes, accounting for 6.8% of all deaths among people 
aged 20-79 years. Globally, by 2030, the number of people with diabetes is expected to 
double (19). Because diabetes’ complications are long term, treatment for diabetes and 
its complications are costly. Global healthcare expenditures to treat and prevent 
diabetes and its complications were estimated to be at least 376 billion US dollars (USD) 
in 2010 and projected to be USD 490 billion by 2030 (20).  
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2.2.2 General background  
In Canada in 2006-07, approximately 2 million Canadians, or 6.2% of the 
Canadian population, were diagnosed with diabetes – an increase of 21% from 2002-03 
(21). There were 211,168 incident cases of diabetes reported in Canada between 2006 
and 2007 (21). The age-standardized prevalence of diagnosed diabetes varies 
geographically in Canada, with higher prevalence in several of the eastern provinces 
(e.g., Newfoundland and Labrador, Nova Scotia, and New Brunswick) as well as 
Manitoba and lower prevalence in the west (e.g., Alberta, British Columbia, and 
Saskatchewan) (21).  
Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) are 
considered to be intermediate conditions between normal blood glucose levels and 
diabetes. They will also be referred to as the prediabetes stage in later parts of this thesis. 
T1DM is insulin dependent and results from a lack of insulin. Although T1DM occurs 
mostly among children and young adults, it may appear among all age groups (18). 
T2DM results from insulin resistance and eventually from a decrease in insulin 
efficiency. Factors that are related to T2DM may include age, obesity, physical 
inactivity, diet, insulin resistance, family history of diabetes and GDM (19). A 
diagnosis of T2DM is more common after 40 years of age, but some cases are 
diagnosed earlier.  
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2.2.3 Epidemiology of diabetes among Aboriginal people in North America 
Aboriginal people are more likely to develop T2DM than other Canadians. The 
First Nations Regional Longitudinal Health Survey (RHS) (2002/2003) reported the 
prevalence of diagnosed diabetes among FN adults to be 19.7%, with most of the cases 
being T2DM (22). FN people experience a higher prevalence of diabetes than the 
general population in every age group. In addition, the RHS report described diabetic 
people on reserves to be much younger than other Canadians with diabetes; that is, 65% 
of FN diabetic people on reserves were 45 years old or younger, whereas the average 
age of diabetic people in the general population is typically over 60 years of age.  
Dyck et al. (23) studied the epidemiology of diabetes among FN and OSK between 
1980 and 2005 in Saskatchewan and reported a higher incidence and prevalence of 
diabetes among FN people, shown in Figure 2.1 and  
Figure 2.2. It has been shown that most new cases of diabetes in FN people occur at 
the age of 40-49 years; however, most new cases of diabetes in OSK people appear 
among those 70 or older. Similar findings have been reported in other Canadian 
provinces. For example, in Alberta from 1995 to 2005 (24), the age- and sex-adjusted 
prevalence of diabetes among FN people was approximately twice that of non-FN 
people. Similarly, in Manitoba between 1989 and 1998 (25), the age-standardized 
prevalence of diabetes was 4.5 times higher among FN people than among non-FN 
people.  
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Figure 2.1 Age-standardized diabetes incidence by ethnicity and sex (23). 
 
 
Figure 2.2 Age-standardized diabetes prevalence by ethnicity and sex (23). 
2.2.4 Etiology and risk factors for Type 1 diabetes 
T1DM and T2DM involve different underlying mechanisms. T1DM is 
“characterized by reduced beta cell numbers in the pancreas, which results in insulin 
production deficiency and is often caused by T-cell’s autoimmune attack, which leads 
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to beta cell loss” (26). Genetic factors associated with the development of T1DM may 
include human leukocyte antigen class II genes (26). A variety of environmental factors 
have been associated with the development of T1DM, such as viruses, insufficient 
breastfeeding duration and increased maternal age. Coxsackie virus B infection is 
proposed to have effects on the pancreas and may also be related to T1DM (26). Early 
diet may play a role in development of T1DM later in life. For example, Harrison and 
Honeyman (27) found that children who were breastfed for a longer period had a lower 
risk of developing T1DM. 
2.2.5 Etiology and risk factors for Type 2 diabetes 
For T2DM, risk factors may include age, overweight, obesity, physical inactivity, 
IGT, GDM, hypertension, and decreased high-density lipoprotein cholesterol (28). The 
importance of genetic and environmental factors in the etiology of diabetes varies 
among populations (29). It was suggested recently that the dramatic increases in the 
rates of T2DM can be primarily attributed to increases in obesity (30). In addition to 
general obesity, body fat distribution is considered another risk factor for T2DM, 
particularly “central obesity”. Central obesity is also known as abdominal obesity, 
characterized by an accumulation of fat around the waist (31). Recently, the 
relationship between excess BMI duration and diabetes incidence was examined by 
Lee et al.(32). One longitudinal study was performed with 8,157 adolescents and 
young adults aged 14 to 21 years from 1981 to 2006. Self-reported diabetes status, 
height and weight were recorded for each participant. Excess BMI-years was the 
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exposure factor. To calculate this indicator, actual BMI was first subtracted from the 
reference BMI for each person in each study year, and then the excess BMI for the 
whole study period was calculated. The results from that study showed that long 
excess BMI duration increases the risk of diabetes.     
A high prevalence of obesity has been documented among many Aboriginal 
populations. The 2004 Canadian Community Health Survey (CCHS) (33) indicated 
that 23.1% of Canadians aged 18 years and older were obese, compared to 13.8% in 
1978/1979. In the same study, the proportion of Aboriginal people who were obese was 
37.6%, almost 1.6 times higher than that among the general population. 
Regular physical activity is considered helpful in preventing and managing T2DM. 
Helmrich et al. (34) examined physical activity and its relationship with later 
development of T2DM. They reported that incidence rates of diabetes decreased as 
physical activity increased. The protective effect of physical activity was strongest 
among people who were at greatest risk of T2DM, such as those with a parental history 
of T2DM, a high body mass index (BMI) and a history of hypertension.  
Investigations with Aboriginal people have also shown that a traditional lifestyle 
may be protective against the development of T2DM. For example, Schulz et al. (35) 
assessed the relationships between T2DM and risk factors such as obesity, physical 
activity, and diet among Pima Indians in Mexico compared to Pima Indians in Arizona. 
These two Pima groups are closely related to each other and share extensive genetic 
similarity. The results indicated that compared to U.S. Pima Indians, Mexican Pima 
Indians have significantly higher physical activity levels and a diet with a lower 
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percentage of calories. The age- and sex-adjusted prevalence of T2DM for Mexican 
Pima Indians was less than 20% of that in U.S. Pima Indians, which provides evidence 
that loss of a traditional lifestyle and adoption of a Western lifestyle may be associated 
with the T2DM epidemic.  
2.2.6 Etiology and risk factors for gestational diabetes 
GDM is defined as “carbohydrate intolerance with first onset or recognition during 
pregnancy” (26). In 2002, Dyck et al. (36) compared rates of GDM between Aboriginal 
and non-Aboriginal women in the Saskatoon Health District, reporting the prevalence 
of GDM as 3.5% and 11.5% for women from the non-Aboriginal population and 
Aboriginal population, respectively. Aboriginal ethnicity was an independent predictor 
for the development of GDM.  
Common risk factors identified for GDM included being pregravid overweight or 
obese, previous pregnancy with GDM, IGT, advanced maternal age, a family history of 
T2DM, and previous delivery of children with a high birth weight (36, 37). GDM may 
result in maternal and fetal risks, such as recurrent GDM (38), early development of 
diabetes for both mother and offspring (39), and macrosomia (40).  Pettitt et al. (41) 
investigated the long-term effects of GDM on the offspring of Pima Indians. The 
findings from this study suggest that intrauterine exposure to diabetes may be an 
important factor for the development of diabetes later in life. Osgood et al. (42) 
investigated the effect of GDM on the development of T2DM in Saskatchewan by 
constructing a population-based simulation model to understand the inter/intra- 
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generational interactions of GDM and T2DM. This study suggested that GDM 
contributed to between 19% and 30% of T2DM among FN in Saskatchewan.  
2.3 Epidemiology of CKD 
2.3.1 Introduction 
The kidneys help to excrete waste products arising from normal body functions. 
These waste products include creatinine which is produced from muscle metabolism.   
Because serum creatinine  is completely filtered and excreted by normal kidneys,the 
serum creatinine level can be  used to estimate the glomerular filtration rate (GFR), 
which is defined as the per-minute filtered output produced by the  kidneys’ glomeruli. 
Thus, the GFR will decrease when kidney function is impaired and this will be 
detectable by an increase in serum creatinine (43). Using serum creatinine to estimate 
GFR, chronic kidney disease can be divided into five stages (44): 
“Stage 1: kidney damage is indicated by leakage of small amounts of albumin into the 
urine (microalbuminuria), but there is a normal or above-normal glomerular 
filtration rate (GFR≥90 mL/min/1.73 m2).  
Stage 2:  kidney damage is often indicated by   increasing microalbuminuria. GFR is 
slightly decreased at ranges from 60-89 mL/min/1.73 m
2
.  
Stage 3: Microalbuminuria may have progressed to  macro-albuminuria. There is a 
moderate reduction in GFR (30-59 mL/min/1.73 m
2
).  
Stage 4:  kidney  damage worsens and GFR ranges from 15-29 mL/min/1.73 m
2
.  
Stage 5: severe kidney failure (GFR<15 mL/min/1.73 m
2
). Treatments such as 
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hemodialysis, peritoneal dialysis and kidney transplantation are needed for 
patients to survive. ” 
To monitor the progression of CKD, routine measurement of serum creatinine is 
needed. By early detection and treatment, patients with CKD may delay the progression 
of CKD and prevent adverse outcomes related to CKD (8). The prevalence of CKD can 
be determined by using  equations that  estimate GFR. The Modification of Diet in 
Renal Disease Study (MDRD) equation and the adjusted Cockcroft-Gault (CG) 
equation have been used in different studies, which increases the difficulty of 
evaluating and comparing epidemiological articles. Zhang et al. (45) systematically 
reviewed population-based studies of the prevalence of CKD and concluded that the 
MDRD equation is used more frequently than the CG equation in recent epidemiology 
studies and stated that the precision of the equations in estimating GFR needs to be 
further investigated.  
2.3.2 Epidemiology of CKD 
 In 2008, an estimated 36,638 Canadians were receiving treatment for ESRD. Recent 
Canadian costing studies suggest that the annual cost per ESRD patient is 55,466 
Canadian dollars (46). Diabetes is the most common cause of ESRD, accounting for 
53.8% of incident cases in 2009, up from 26.9% in 1996 (2, 3). In the United States, 
Coresh et al. (47) compared two samples from the National Health and Nutrition 
Examination Survey (NHANES) (NHANES 1988-1994 and NHANES 1999-2004) 
and found that the prevalence of CKD had increased; that is, the prevalence of 
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individuals with stage 1-4 CKD increased from 10% during 1988-1994 to 13.1% during 
1999-2004. It was proposed that the increase in CKD may be due to concomitant 
increases in the prevalence of diabetes and hypertension.  
2.3.3 Complications of CKD 
Complications that may develop during CKD include hypertension, malnutrition, 
bone disease, and anemia (44). Mortality rates from coronary artery disease and strokes 
are high among patients with late stages of CKD (stages 3 and 4) , and most patients die 
without developing ESRD (48, 49). Dialysis and renal transplantation are  initially 
lifesaving after the development of ESRD. However, estimates from the US Renal Data 
System showed that for patients who started dialysis in 2001, the 3-year survival 
probability was only 54% (50). In Saskatchewan, it was estimated that the median 
survival time after the diagnosis of diabetic ESRD was only 2 years (6). Among 
patients with pre-ESRD CKD, death is a more common  complication than is ESRD 
(51).  
2.3.4 Epidemiology of CKD among Aboriginal population. 
Aboriginal people experience higher rates of ESRD than non-Aboriginal people. In 
Saskatchewan in 1994, Dyck and Tan (52) found that the incidence of diabetic ESRD 
was higher among Aboriginal people than non-Aboriginal people during a 10-year 
period. Similarly, Nelson et al (53) found that among 45-64-year-olds, the incidence of 
ESRD among diabetic Pima Indians was 14 times higher compared with the rate among 
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the United States diabetic population. One recent study in Saskatchewan showed that 
FN with diabetes had higher rates of ESRD when compared with OSK with diabetes 
(Figure 2.3 and Figure 2.4) and that FN were significantly younger when diagnosed 
than were OSK (6). Among OSK people, males experienced higher rates of ESRD than 
did females, while the difference in ESRD incidence between FN males and FN 
females varied during the study period.  
 
Figure 2.3 Age-standardized ESRD incidence among subjects with diabetes (6). 
 
Figure 2.4 Age-standardized ESRD prevalence among subjects with diabetes (6). 
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The difference between Aboriginal populations and non-Aboriginal populations in 
the prevalence of CKD varies among stages of CKD (8). Gao et al. (8) have shown the 
overall age- and sex-adjusted prevalence of CKD to be higher among FN compared 
with non-First Nations Canadians. After stratifying CKD by stages, they found that 
age- and sex-adjusted rates of CKD are even higher among First Nations for the more 
severe stages of CKD.  
Ethnic differences in the prevalence of CKD between African-Americans and 
non-African-Americans were examined in one cohort study in the United States (54). 
The MDRD equation for estimated GFR (eGFR) was used, and this study showed that 
after adjustment for other individual factors, the black-to-white odds ratio was 0.42 at 
an eGFR of 50 to 59 ml/min/ 1.73 m
2
 and increased to 1.73 at an eGFR of 10 to 19 
ml/min per 1.73 m
2
.  
2.3.5 Risk factors for CKD 
Both genetic and environmental factors may play roles in the development of CKD 
(55, 56), and they may include age, hypertension, diabetes, obesity and smoking. One 
10-year cohort study performed by Yamagata et al (57) has shown several risk factors 
for the development of CKD. Among 123,764 people aged 40 years and older, for 
females, the development of CKD stage 1 or 2 was most strongly related to age, 
hypertension, IGT, diabetes, obesity, and current smoking. For males, the development 
of CKD stage 1 or 2 was most strongly associated with the same factors in addition to 
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alcohol consumption.   
Regarding genetic factors, there is evidence for family clustering of diabetic renal 
disease among Aboriginal populations (58). Pettitt et al (58) found that after adjusting 
for sex and other risk factors, proteinuria occurred among 22.9% of diabetic offspring 
with at least one parent having diabetes and 45.9% of diabetic offspring with both 
parents having diabetes. There is also a relationship between high blood pressure and 
diabetic nephropathy (44). Genes that encode proteins that are related to hypertension 
might be associated with diabetic nephropathy (44). It was proposed that the 
angiotensin I-converting enzyme gene is an independent risk factor for renal disease 
and is associated with an increased rate of diabetic kidney disease progression (59, 60).  
Regarding environmental factors, intrauterine exposure to diabetes may be relevant 
to diabetic renal disease among mothers and their offspring (61). Mothers who have 
GDM may develop T2DM and diabetic ESRD later in life. The offspring of mothers 
with GDM may have a higher risk of diabetes when they reach childbearing ages, and 
they have a higher risk of developing diabetic renal disease than those not exposed to 
intrauterine diabetes. Nelson et al. (61) found that the risk of increased urinary albumin 
excretion among offspring of diabetic mothers was nearly four times that among 
offspring of non-diabetic or pre-diabetic mothers. Moreover, Dyck et al. (62) reported 
that diabetic pregnancy may increase the risk of diabetic ESRD and that intrauterine 
exposure to diabetes may be one environmental factor for the development of diabetic 
renal disease among mothers and their offspring. 
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2.3.6 Summary  
Aboriginal populations experience higher rates of CKD compared with 
non-Aboriginal populations. Risk factors for CKD may include age, hypertension, 
IGT, diabetes, obesity and smoking. Diabetes is reported to be the most common 
cause of ESRD. Patients with ESRD need to take costly treatments such as dialysis 
and kidney transplantation. Death rates are reported to be high among CKD patients.  
2.4 System Dynamics modeling and agent-based modeling for public health 
System Dynamics modeling (SDM) is suitable to help understand complex 
dynamic behaviors of health care systems and health of the population (11). SDM 
simulates the systems at an aggregate level with the inclusion of characteristics such as 
causal loops, delays and interactions among components of the modeled system (15). 
Agent-based modeling (ABM) is useful to help in understanding the behaviors of 
autonomous agents and the emergent performance of the system in which these 
individuals circulate (63). Once either System Dynamic models or agent-based models 
have been validated, we can perform simulation experiments to ask certain “what if” 
questions (10, 15). For example, with diabetic ESRD models, it is possible to 
understand how the number of ESRD cases might change if we were to lower diabetic 
mortality.  
SDM has been used in public health to understand the evolution of complex 
health systems and health of populations over time (11). With a validated System 
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Dynamic model, experiments under certain scenarios could be conducted. For 
example, Jones et al. (13) used system dynamic modeling to understand diabetes 
population dynamics. The simulation results help understand the effects of factors 
such as obesity and clinical management of prediabetes and diabetes on the change of 
the prevalence of diabetes. Figure 2.5 presents an overview of the System Dynamics 
model of the diabetic population in Jones et al. (13). The whole population is divided 
into several stages according to blood glucose level and diagnosis status. Flows are 
represented as arrows such as the progression from undiagnosed, uncomplicated 
diabetes to undiagnosed complicated diabetes. This model also includes factors 
related to interventions. The factors are represented in italics such as the obese 
fraction of the population, management of prediabetes, self-monitoring, etc. Mainly, 
three interventions were compared and discussed: enhanced clinical management of 
diabetes, increased management of prediabetes, and reduced obesity prevalence. The 
simulation results showed that increased clinical management of diabetes was able to 
lower the prevalence of death, but due to a “backing up” effect, the prevalence of 
diabetes increased. The intervention focusing on increased management of 
prediabetes helped to reduce the prevalence of diabetes and death, but could not halt 
the increases of both events. By contrast, it was found that an intervention that 
reduces obesity prevalence could reduce the prevalence of both diabetes and death 
and meanwhile stops the growth in the prevalence of diabetes and death (13). 
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Figure 2.5 Overview of model structure with population stocks and flows and policy 
related intervention (shown in italics) (13). 
SDM also has been used as a tool to evaluate objectives of health care policies 
(14). Simulation results suggested that a stated objective of 38% reduction in the 
prevalence of diagnosed diabetes in the United States in Healthy People 2010 is 
unlikely to be met, and diabetes prevalence is more likely to continue increasing since 
there are more new diabetes cases than deaths of diabetes. Moreover, there are 
conflicts among objectives. For example, the objective to increase detection rate of 
diabetes and to reduce the diabetic mortality rate are in conflict with the objective to 
lower the prevalence of diabetes. The first two objectives would actually increase the 
prevalence of diabetes. 
Furthermore, SDM was used to make prediction of the ESRD population in Japan 
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in 1991 (12). There were two scenarios tested using the validated model: a successful 
increase or a failure to increase the rate of kidney transplantation. The model's 
simulation results showed that with no increase of kidney transplantation rate, the 
number of ESRD patients would be 157,350 while the number would drop to 145,750 
if the increase in the rate of kidney transplantation is successful. Moreover, under the 
second scenario, annual medical expenditure from dialysis of ESRD patients would 
drop by about 38.6 billion yen.  
ABM is useful to help in understanding the behaviors of autonomous agents and the 
emergent performance of the system in which these individuals circulate (10, 63-66). 
Hammond (64) discussed using ABM to study the complex dynamics of obesity 
epidemic and to design policy and intervention. In this study, characteristics of 
epidemic of obesity were reviewed, such as wide range of scale levels, huge diversity 
of factors that could affect energy balance, different mechanisms, and interactions and 
feedbacks among mechanisms. ABM was proposed to be a useful methodology to 
study the complex dynamics of obesity by addressing attributes of obesity epidemic. 
Moreover, ABM could also be useful to act as a computational laboratory assisting in 
understanding “what if” and test different intervention policies (64, 65). 
ABM has also been used in the contest of infectious disease. Figure 2.6 presents 
one ABM model for tuberculosis (TB) transmission with smoking as a risk factor (66). 
Two parts related to one person’s status were captured. One is status of TB, such as 
uninfected state, latent state and active TB state. The other classification captured 
related to smoking. One SDM model was also built for TB transmission with smoking 
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being a risk factor. Results from ABM and SDM were compared in this research work, 
and it was concluded that SDM is a continuous deterministic model and gives only 
one trajectory of outcome, but stochastic ABM captures stochastic variability in 
evolution, and – by running a set of Monte Carlo simulations – can be employed to 
capture the range of outcomes that might be expected. Moreover, it has been 
discussed that SDM assumes that population is well mixed and is infeasible to 
incorporate large amounts of heterogeneity, network topologies, and history 
information, all of which are readily incorporated in ABM models.  
 
Figure 2.6 Structure of agent-based model of TB diffusion with the effect of smoking 
(66)   
 
In summary, both SDM and ABM methods have been used in the context of 
public health to understand complex dynamics of health system and evaluate policy 
interventions. Both methods will be used in the context of competing risks of ESRD 
and death without ESRD. The basic components and definition of SDM and ABM 
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will be discussed in the Methodology sections 5.3 and 5.4 of this thesis.  A 
Comparison of the methods in the context of this work is included in the Discussion 
section. 
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Chapter 3 Rationale 
ESRD disproportionately affects Aboriginal people in Canada. The reasons for the 
greater rates of diabetic ESRD among FN with diabetes compared to OSK with 
diabetes may include an increased onset rate of diabetic glomerulosclerosis that may 
result in ESRD (7); higher rates of kidney function loss after onset of CKD (7); and/or 
reduced mortality during pre-ESRD stages of CKD (7). We briefly expand on these 
hypotheses below. 
First, there is an increased prevalence of micro- and macro-albuminuria among FN 
people when compared to other Canadians. In a study of diabetic FN by Hanley et al. 
(67), FN people experience higher rates of micro- and macro-albuminuria compared 
with non-FN people. Increased rates of diabetic glomerulosclerosis may lead to higher 
rates of ESRD (7). 
Second, increased speed of kidney function loss may lead to a higher prevalence of 
severe CKD among FN than non-FN people, leading to higher rates of ESRD. If kidney 
function is lost rapidly, the prevalence of pre- and stage 1 CKD as well as later stages of 
CKD before ESRD should be high (8, 51). Although Gao et al. (8) reported an overall 
lower prevalence of CKD among Aboriginal than non-Aboriginal people, the 
prevalence of late-stage CKD among First Nations people was almost twice as high as 
that among non-First Nations people. This suggests that rapid kidney function loss may 
lead to increased rates of ESRD.  
Third, FN people may have enhanced survival before reaching the stage of ESRD, 
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resulting in a higher rate of ESRD development. Death without ESRD is a competing 
risk event for ESRD cases and is common among people who have CKD (68). One 
study in Saskatchewan by Dyck et al. (7) found that diabetic FN with early stage CKD 
(eGFR ≥30 ml/min) experienced a older age- and sex-adjusted risk of death compared 
with diabetic OSK. However, mortality risks for people at the pre-ESRD stage of CKD, 
with and without adjusting for age and sex, were lower among FN than OSK. This is 
likely to reflect the fact that FN people typically acquire diabetes at a significantly 
younger age than do non-FN people. 
This study will be the first, to our knowledge, that examines disparities in the risks of 
ESRD and mortality and estimates the simultaneous risks of these two events between 
FN and OSK using competing risks survival analysis in the population of 
Saskatchewan. Simulation modeling is useful for evaluating the accuracy of the hazard 
rate estimations. A better understanding of these disparities will help to target research, 
intervention and disease management to decrease the ethnic disparities, such as 
applying the knowledge to more effective diabetes and CKD prevention and CKD 
management initiatives.  
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Chapter 4 Study objectives 
1. To increase our understanding of why there are disparities in ESRD rates between 
FN and OSK with diabetes. 
a. To determine whether there are significant disparities in the risk of ESRD 
development between FN and OSK. 
b. To determine whether there are significant disparities in the risk of mortality 
without ESRD between FN and OSK. 
2. To build Saskatchewan diabetic ESRD dynamic models. 
a. To estimate the hazard rates for ESRD and mortality without ESRD and to 
build a dynamic model using hazard rate estimations. 
b. To validate models by comparing model-predicted data with historical data. 
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Chapter 5 Methodology 
5.1 Study design and participants 
Administrative databases were used to collect cohorts of First Nations (FN) people 
and other Saskatchewan (OSK) people with diabetes and ESRD between 1980 and 
2005. This study received approval from the University of Saskatchewan Ethics 
Review Board. The detailed description of the study populations can also be found in 
two publications by Dyck et al. (6, 23). 
The total population was then divided into FN and OSK as follows. FN people in 
this study are people who are indigenous to Canada. FN people are registered under 
Section 6 of the Indian Act of Canada and are beneficiaries of universal health care. 
OSK in this study population are a group of people who have predominantly European 
origin but also include non-registered FN (<0.5%) and Métis (approximately 5%) (6, 
23). 
The diabetes case definition required one hospital discharge for diabetes (Hospital 
Service database), two physician service claims from the Physician’s Service database, 
or a physician service claim and then a hospital discharge for diabetes within 730 days. 
We excluded gestational diabetes cases from the study population and only included 
type 1 and type 2 diabetes. The ESRD case definition was based on physician service 
codes for chronic dialysis and also included renal transplantation. In addition, chronic 
dialysis was defined as 90 days’ dialysis with no break for more than 21 days. In the 
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study population of diabetics, the causes of ESRD were not distinguished by etiology (6, 
23). 
After defining people who had diabetes and ESRD, we then obtained 
supplementary information, such as sex, ethnicity, birth year, year at diagnosis of 
diabetes, and year at ESRD diagnosis, as well as year of death and loss of health care 
coverage if those occurred.  
In our study, people who developed ESRD before diabetes were excluded from the 
study population, but they remained if they were diagnosed with both diseases in the 
same year. Death without ESRD was treated as a competing risk event with ESRD, but 
death after the development of ESRD or in the same year as ESRD development was 
not considered a competing risk event. Moreover, we excluded people who were 
younger than 20 years old at the time of their diabetes diagnosis so that we could 
exclude most type 1 diabetes cases. 
5.2 Statistical analysis 
5.2.1 Introduction 
Descriptive statistics were used to gain information about distributions of variables, 
such as diabetes diagnosis age and ethnicity. Comparisons between groups were 
performed using t-tests and χ2 tests, The significance level was set to 0.05.  Competing 
risks survival models were used to model the relationship between predictors and 
outcomes. Cox cause-specific model, Weibull proportional hazards model and 
piece-wise exponential proportional hazards model were used. Predictors in our study 
 28 
 
included diabetes diagnosis age, sex and ethnicity, and there were two outcomes: ESRD 
and death without ESRD.   
Survival analysis is “an application of a collection of statistical procedures for data 
analysis for which the outcome variable of interest is time until an event occurs” (69). 
One straightforward method for survival analysis is a non-parametric method, such as 
the life table method introduced by Berkson and Gage (70). Another non-parametric 
method was proposed by Kaplan and Meier (71). Non-parametric methods can be used 
to analyze one sample of survival data or to compare two or more groups of survival 
data. Moreover, supplementary information can be recorded for individuals, such as 
age, sex and ethnicity. These variables can be referred to as explanatory variables. 
Non-parametric methods cannot be used to determine the effects of explanatory 
variables on survival times. The Cox proportional hazards (PH) model can be used to 
analyze survival data with explanatory variables (72). Sometimes, if the data follow a 
particular probability distribution – such as the exponential distribution, Weibull 
distribution or Gompertz distribution – we can use parametric survival analysis to test 
hypotheses and also to estimate hazard rates at the individual level, given certain 
characteristics of individuals. 
We first give the following definitions of an event, survival time and censoring (69). 
An “event” denotes a death or disease incidence that may happen to an individual in a 
certain study. The “survival time” means the number of time units (e.g., years, months, 
weeks, or days) from the beginning of the follow-up period until an event occurs. In our 
study, time means years since diabetes diagnosis. Censoring happens when part of an 
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individual’s survival time is partially known, but we do not know the whole survival 
time exactly. Here, we will discuss the right censoring that happened in our study (69). 
In each of these situations, a patient who entered a study at time t0 experienced an event 
of interest at time t0+t. However, t was unknown, either because the individual was still 
alive or because he or she had been lost to follow-up. If the individual was last known to 
be alive at time t0+tc, the time tc is called a censored survival time. Right censoring 
occurs when censored survival time is less than the actual but unknown survival time 
(69).   
Survivor Function 
Two functions can be used to describe survival data: the survivor function and the 
hazard function (69, 72). Variable T is a random variable denoting the actual survival 
time t, (T>0). The probability density function for T is f(t). The cumulative distribution 
of T is given by  
0
( ) ( ) ( )
t
F t P T t f u du                         (5.1) 
and represents the probability that the survival time is less than time t. The survivor 
function S(t) is defined as the probability that the survival time is greater than or equal 
to t, given by 
( ) ( ) 1 ( )S t P T t F t                        (5.2) 
and therefore is used to represent the probability that an individual survives from the 
start time until a time equal to or beyond t. 
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A hazard function expresses the hazard risk of an event at some time t, 
conditionally that person has survived until time t . The formula for h(t) is shown 
below: 
0
( )
( ) lim
t
P t T t t T t
h t
t


     
  
                       (5.3) 
 
is called the cumulative hazard function.  
5.2.2 Non-parametric methods 
An initial step in the analysis of survival data is to present numerical or graphical 
summaries of the survival time. Non-parametric methods can be used to estimate 
survival data through estimations of the survivor function and hazard function. This 
method does not require any specific assumptions regarding the distribution of the 
survival time (72). 
The Kaplan-Meier estimate of the survival function 
To obtain a Kaplan-Meier (K-M) estimate, we first create a series of time intervals 
based on the time of events (72). In each interval, there is only one event that happens at 
the beginning of the interval. Suppose that there are n individuals with observed 
survival times t1, t2, … , tn during this period of time, with some of these observations 
being right censored. There are r event times, and r is smaller than or equal to n, and 
after arranging time in ascending order, the jth time interval is denoted tj, for j=1, 2, …, 
r, and so the r ordered times are t1<t2<…<tr. The number of people who are alive just 
before time tj is nj, for j=1, 2, …, r, and dj will denote the number of individuals who 
0
( ) ( )
t
H t h u du 
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experience the event at time tj. The time interval from tj - δ to tj, where δ is an 
infinitesimal time, includes only one event. The probability for an individual to 
experience the event during this interval is estimated to be dj/nj. Therefore, the 
probability for an individual to survive through that interval will be (nj-dj)/nj. Therefore, 
the K-M estimator of S(t) for tk≤t<tk+1, k=1,2,…r is defined as: 
                      (5.4)                   
representing the probability of surviving through interval tk to tk+1 and all preceding   
intervals (72). 
Hazard Function 
Smoothed plots of hazard rates are used often in practice, and they can give us an 
understanding of the shape of hazard curves, thereby allowing us to assume the 
distribution of survival time. The Epanechnikov kernel smoothed estimate of hazard 
function is used (72, 73), and it is based on r ordered death times, t(1), t(2),…t(r),
 
( )† 1 2
1
( ) 0.75{1 ( ) }
r
j j
j j
t t d
h t b
b n



 
               (5.5) 
with dj deaths and nj at risk at time t(j), and t is defined on the time interval (b, t(r)-b). 
The parameter b is named bandwidth, and we can obtain an optimal estimation for it. 
For any time point t, death time in interval (t-b, t+b) is used to estimate hazard rate at 
time t.  
1
-
( ) ( )
k
j j
j j
n d
S t
n

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5.2.3 Cox proportional hazards model 
The non-parametric methods described above can be used to describe one group of 
survival data or compare survival time between two groups – for example, a 
comparison of survival time between FN and OSK following diabetes diagnosis. 
However, there are situations in which more information about patients – referred to as 
explanatory variables in the dataset, such as age, sex, ethnicity, and blood pressure – 
can be obtained. Researchers often wish to determine whether there are relationships 
between these exploratory variables and survival time. To accomplish these aims, 
statistical modeling procedures should be used. The Cox proportional hazards (PH) 
model (72), which is commonly used to explore how exploratory variables impact 
hazard ratios. Suppose that the event hazard at a specific time depends on the values x1, 
x2, ..., xp of p explanatory variables X1, X2, …, Xp.  Let hi(t) be the hazard function for 
the ith individual at time t. We call the hazard function for a person for whom the values 
of all the explanatory variables are zero the baseline hazard function, denoted as h0(t).   
The Cox PH model can be expressed for the ith person at time t as follows: 
0 1 1 2 2( ) ( )exp( ... )i i i p pih t h t x x x                     (5.6)
 
where x1i, x2i,…., xpi are the values of p exploratory variables for the ith person, and β1, 
β2,…., βp are the coefficients of the corresponding explanatory variables. 
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5.2.4 Parametric proportional hazards model 
In the Cox cause-specific model, there is no assumption required regarding the 
distribution of survival time. If a certain distribution for survival time is valid, we may 
use the parametric model to test the effect of explanatory variables and estimate hazard 
rates with explanatory variables information included in the estimation of hazard rates. 
The Weibull PH model and exponential PH model will be discussed below.  
5.2.4.1 Weibull proportional hazards model 
Under the Weibull PH model, the hazard of an event can be expressed with scale 
parameter λ and shape parameter γ, (λ>0, γ>0), and the hazard function of one ( , )W  
distribution is given by 1( )h t t  . Under the Weibull PH model, the hazard 
function of the ith person at time t with covariates (x1i, x2i, …,xpi) can be shown as: 
1 1
1 1 2 2( ) ( ) exp( ... ) ( ) exp( ' )i i i p pi ih t t x x x t X
                 (5.7) 
' iX indicates β1x1i + β2x2i + …βpxpi. Therefore, we can say that the survival time of the 
ith person at time t follows Weibull distribution with scale exp( ' )iX   and shape 
parameter .    
exp( / )                             (5.8)                      
1/                                (5.9)                           
      βm = -αm                              (5.10) 
m=1, 2, …, p and µ, γ, αm can be estimated from statistical analysis procedures. 
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5.2.4.2 Exponential PH model 
The exponential PH model (72) assumes that the hazard function is constant over 
time (72). The hazard function under this model can be written as h(t)=λ, for 0≤t< . λ 
can be estimated by fitting the model to the observed data, and it is a positive constant. 
Under the exponential proportional hazards model, the hazard function of a 
particular ith patient at time t may be given as: 
1 1 2 2( ) exp( ... )i i i p pih t x x x                  (5.11) 
With β1, β2. βp being coefficients of explanatory variables, with 
exp( )                            (5.12) 
 βm= -αm                           (5.13) 
and with m=1, 2, …p, similar to the Weibull PH model, we can obtain the estimates of 
µ, αm from 
statistical analysis. 
5.2.4.3 Piece-wise exponential proportional hazards (PH) model 
The piece-wise exponential PH model (74) is an extension of the exponential 
proportional hazards model. For constructing a piece-wise exponential model, we first 
need to specify a time grid τ = {s0, s1, s2,……sk} and 0=s0<s1<s2……<sk<∞. Then, the 
time axis is divided into p intervals Ij = (sj-1, sj], for j=1,…, k. Then, we assume that the 
hazard rate during each interval of the grid τ is constant, which means that for t ∈ Ij, 
j=1,…k: 
( ) jh t                            (5.14) 
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Under the piece-wise exponential proportional hazards model, the hazard function 
of a particular ith patient at time t for time interval Ij, where t∈ Ij, and j=1,…k may be 
given: 
1 1 2 2( ) exp( ... )i j i i p pih t x x x                   (5.15) 
where β1, β2,…., βp are coefficients of exploratory variables. We can determine µ, αm 
from statistical analysis, with m=1, 2, …p 
βm= -αm                                (5.16) 
To compare parametric models, we can use statistical tests such as the likelihood 
ratio (72) test or Akaike’s information criterion (AIC). The likelihood ratio test can be 
used to compare nested models such as the exponential distribution, Weibull 
distribution and gamma distribution, while AIC can be used to compare models that are 
not nested. AIC is defined as  
2logAIC L q                        (5.17)                     
where L  is the estimated maximized likelihood for one model, q is the number of 
explanatory variables, and α is a predetermined constant value. After fitting one model 
to survival data, we can obtain an AIC value for the fitted model. The smaller AIC is, 
the better the model was fitted.  
5.2.5 Competing risks survival analysis 
Competing risks occur when a person experiences a chance of two or more events 
(69). For example, Figure 5.1 presents one situation of competing risks. One diabetic 
patient may die before they develop ESRD; therefore, death without ESRD and ESRD 
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are competing risk events for people with diabetes. One person with diabetes can only 
experience either of these possible events at one time (75). 
 
 
 
  
 
 
 
Figure 5.1 Competing risk events. 
 
 
 
5.2.5.1 Cause-specific hazard function 
   First, we give the definition of a cause-specific hazard function as:  
0
( , | )
( ) lim c cc
t
P t T t t C c T t
h t
t 
    


                (5.18) 
Tc is time to failure from event c, c=1, 2,…., C, where C is the number of event types 
(69).   
5.2.5.2 Cumulative incidence function  
Another nonparametric method is to use a cumulative incidence function (CIF), 
which indicates the probability of certain event (e.g., ESRD or death without ESRD) 
before some point in time. To calculate CIF, we need several estimations from the data, 
including the Kaplan-Meir estimator and cause-specific hazard. First we order the event 
ESRD 
Death without 
ESRD 
People with Diabetes 
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time t1<t2<…<tr and make dcj the number of events of type c at time tj. At time tj, the 
number of people at risk is nj. ( )S t is the Kaplan-Meir estimator of the probability of 
being event free by time t, and c jh  is the cause-specific hazard for event c at time j. 
CIF for event type c can be given by (69): 
1
,
( ) ( )
j
jcc j
j t t
F t h S t 

                        (5.19) 
The cause-specific hazard at time tj can be expressed as dcj/nj. Therefore, 
1
,
( ) ( )
j
c j
c j
j t t j
d
F t S t
n


                       (5.20) 
5.2.5.3 Cox cause-specific model 
The Cox cause-specific hazard model  is used to analyze competing risk survival 
with a Cox proportional hazards model to estimate hazard ratios between groups for 
each type of failure, treating the other failures as censoring together with withdrawal 
from the study or loss to follow-up (69).  
The Cox cause-specific model for event type c with covariates for the ith patient at 
time t with p covariates X=(x1, x2,…xp) is defined to be: 
0 1
( , ) ( )exp
p
ic i
c c i
h t h t x

    
X                     (5.21), 
c=1, 2, …., C, where C is the number of event types. 
The Cox cause-specific hazard model is used to compare the hazard ratios of 
developing ESRD or mortality between groups such as FN and OSK.  
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5.3 System Dynamics modeling 
After fitting the statistical model to the data set and getting estimates of hazard 
rates, we want to build up a SDM using the subscripting approach to represent the 
Saskatchewan Diabetes and ESRD system. There are several advantages of SDM, such 
as helping to capture the complexity of health system by including many aspects of 
health problems, using prospective simulations to anticipate possible future trends, and 
helping policy makers to evaluate policies by performing what-if experiments within 
the model (76). SDM is most commonly conducted at the aggregate level of modeling, 
where it depicts a series of cross-sectional views of population evolution. 
5.3.1 System Dynamics modeling, first order delay and competing risks 
Stocks and flows are central concepts in System Dynamics. This section first 
introduces these two terms with a diagram and then discusses mathematical 
representation of stocks and flows (76). Figure 5.2 depicts an example stock and flow 
diagram. 
  
Figure 5.2  Stock and flow 
 
Stocks are indicated by rectangles and flows are indicated by arrows. Inflows for a 
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given stock are shown as going into that stock and outflows are shown as going out of 
that stock. Valves on flows control the flows. Clouds can be used to indicate the source 
for an inflow or an outflow’s destination. One can regard the stock as a bathtub with the 
water level representing the value of the stock, such as prevalence of diabetes. The rate 
of inflow can be analogous to the rate of water flowing into the bathtub, while the rate 
of outflow is analogous to the rate of water flow out of the bathtub (76). Stocks and 
flows have mathematical meaning. Stocks integrate the net flow. The structure 
represented in Figure 5.2 can be understood in a mathematical context with the 
following integral equation (76): 
0
0( ) [ ( ) ( )] ( )
t
t
Stock t Inflow s Outflow s ds Stock t  
       (5.22)
 
where Stock(t) represents stock value at time t, and Inflows(s) and Outflows(s) indicate 
the values of inflows and outflows at time s between initial time t0 and time t. 
 
Figure 5.3 First order delay for progression from diabetes to ESRD 
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In SDM, first order delay is a key characteristics and it could be treated as a 
representation of deterministic approximation to a memory-less stochastic process (15). 
The system is called “memory-less” because the chance of a person leaving in the next 
unit of time is independent of how long they have been in the state. A first order delay 
for diabetic population progressing to ESRD or death without ESRD is shown with 
stock and flow charts in Figure 5.3. The following derivation used Dr Osgood’s class 
slide as reference (15). Alpha (α) is the hazard of progressing from “Diabetic 
Population (X)” to “Population with ESRD (Y)”, indicating the probability of 
progressing from diabetes to ESRD per unit time. While α commonly changes in 
System Dynamics models (e.g. for the force of infection associated with epidemic 
spread), for the discussion below, we assume that alpha is a constant. The total change 
in the value of the stock over an infinitesimally small time duration dt is dx. Thus,  
dx x dt                          (5.23) 
dx
dt
x
 
                         (5.24) 
The value of stock x at time 0 is the initial value indicated as x(0), and the value of 
x at time T is x(t).  
0 0
t T t T
t t
dx
dt
x

 
 
  
                      (5.25) 
( )
(0)
Tx T e
x

                      (5.26) 
 41 
 
indicating the fraction of the initial population remaining in the stock at time T. The 
probability of a given person leaving in a time dt conditional on that person having 
remained in the stock up to that time t is always equal to αdt. Hazard rate estimations 
using the piece-wise exponential PH model in Section 5.2.4.3 could be used as 
parameters for rates of proceedings. 
The likelihood that someone leaves between time t and t+dt is P(leaving exact 
between time t and t+dt)= P(person remains in the stock at time t)*P(leaving exactly 
between time t and t+dt| person remains in the stock at time t)=α
te  dt. 
The mean time for people to stay in the stock can be estimated by: 
0 0 0
( ) ( ) 1/T Ttp t dt tp t dt t e dt te dt   
   
 

        
Competing risks of ESRD and mortality are shown with stocks and flows (15) in 
Figure 5.4. There are two outflows from the “Diabetic Population” stock. One flow 
named “Diabetes progressing to ESRD” was directed to the stock of “Population with 
ESRD” and the other, named “Deaths of Diabetic Population”, was also flowing out of 
the stock. Suppose a diabetic population’s initial value is x(0) at time zero, and its value 
at time T is x(T). In the model, a likelihood density named “Rate of progressing from 
Diabetes to ESRD (α)” was used to determine the value of the flow “Diabetes 
progressing to ESRD” and the other likelihood density (named “Annual Risk of 
Diabetic Mortality (β)”) was used to determine the flow “Death of Diabetic 
Population”.  
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Figure 5.4 Competing risks between ESRD and death without ESRD. 
 
The total change in the value of the stock x over an infinitesimally small time 
duration dt is dx. The following derivation used Dr. Osgood’s class slides as reference 
(15). 
( )
dx
x x x
dt
        
                  (5.27) 
Suppose that at time zero, the initial value of the Diabetic Population is x(0), and 
we want to find the value of x at time t.  
( )( ) (0) tx t x e                        (5.28) 
For t>0, P(Person remains in the stock at time t)=
( )te     
P(leaving exactly from diabetes stock to ESRD stock between time t and t+dt| 
Person remains in the stock at time t) = α*dt 
Diabetic
Population (X)
Population with
ESRD (Y)Diabetes progressing
to ESRD
Death of Diabetic
Population
Annual Risk of
Diabetic Mortality
(β)
Rate of progressing from
Diabetes to ESRD (α)
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The likelihood A(t) that someone leaves from the diabetes stock to the ESRD 
stock between time t and t+dt is is P(leaving exact between time t and t+dt)= P(Person 
remains in the stock at time t)*P(leaving exactly between time t and t+dt| Person 
remains in the stock at time t)=α
( )te    dt 
Here α and β are constant. Values for hazard rates α and β can be estimated from 
statistical procedures modeling the likelihood that diabetic people will develop ESRD 
and die, respectively (15). 
5.3.2 Subscripting Dynamics Modeling 
Sometimes during modeling, one piece of a model structure can be repeated several 
times (77). For example, if we divide age at diabetes diagnosis into several age 
categories, the process of developing ESRD will be replicated for different diagnosis 
age categories. One method for summarizing this repeating structure is to create one 
structure and then to replicate that structure several times as needed both visually and 
functionally. Visually, this will lead to complex graphs of stocks and flows, which can 
be confusing to interpret. Even more importantly, changes in that process that apply 
across all of the different instances of that structure will typically need to be made 
manually to each section in turn, in a manner that is tedious and error prone. 
Another way to construct a repeated structure is to use subscripts. We can create 
one original structure and add other structures through the addition of subscript 
elements. Values for each subscript can be changed, and the overall diagrams will look 
clearer. Because of the centralized description of the system across all subscripts, 
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changes can be localized to one point. For example, in the model examined here, we 
need to divide ethnicity into FN and OSK, and we can therefore use subscripts to 
organize diagrams as shown in Figure 5.5. Each subscripted structure can be described 
and given distinct values where required. 
 
Figure 5.5 Subgroup in Vensim 
 
5.4 Agent-based modeling 
“In agent-based modeling (ABM), a system is modeled as a collection of 
autonomous decision-making entities called agents” (63). Agents are able to adapt and 
modify behaviors based on certain rules. An agent-based model is made of a system 
of agents and interactions between them and with an environment. ABM is used to 
describe and simulate a system, and we can first describe the assumptions of 
behaviors of agents and the mechanisms of interaction among them. In this thesis, we 
used Anylogic software as a platform to build and simulate agent-based models. In the 
following subsection, certain typical terminology and representations in Anylogic will 
be discussed, such as state, transition, and branch.  
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5.4.1 Statecharts 
One statechart is shown in Figure 5.6. It is made of an entry point, branch, state and 
transition (10, 78): 
 
Figure 5.6 Statechart. 
 
An event is used to schedule some action in the model and to model delays and 
timeouts. A state chart is used in ABM for describing events and behavior during a 
period of time. States and transitions are two major parts of state charts. Presence in 
states  is controlled by reactions to events. A transition denotes a switch from 
one state to another.  A statechart entry point  is used to indicate the initial 
state of the statechart. There should be exactly one statechart entry point defined for 
each statechart. “A branch  represents a transition branching and/or connection 
point”(78). Once branches are executed, they create conditional transitions to the next 
destination states.  
ABM is typically stochastic in occurrence of certain events, transitions between 
states; therefore, different simulations may show different results for the same model 
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with the same parameters. To derive conclusions that are robust in spite of such 
variation, the Monte Carlo method was used. After performing Monte Carlo analysis by 
running one simulation 100 times, we obtain an array of outputs and show them in a 2D 
histogram. In 2D histogram, we could use envelopes to show percentage of histogram. 
For example, in specifying envelopes as 0.025, 0.05, 0.25, 0.75, 0.95, 0.975, we are 
showing areas containing a given 2.5%, 5%, 25%, 75%, 95% and 97.5% of realization 
results (78). 
5.5 Software 
Statistical analysis for this thesis was performed using SAS 9.2 (SAS Institute, Cary, 
NC, USA). Dynamic Models were constructed by using Vensim DSS 5.5c (Ventana 
Systems, Inc., Harvard, MA, USA) and Anylogic 6.2 Advanced. 
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Chapter 6 Results 
6.1 Description of study population and descriptive analysis 
In total, 108,037 people with diabetes were recorded in the health care system from 
1980 to 2005. After excluding people who developed diabetes before 1980, people 
whose diabetes diagnosis age was less than 20 and those that developed ESRD before 
diabetes, there were a total of 90,429 diabetic people in the study. Figure 6.1 is the data 
extraction flowchart of the study population. Figure 6.2 and Figure 6.3 present data 
extraction flowcharts for both ESRD and death without ESRD among FN and OSK, 
respectively.   
We performed descriptive analysis to characterize the variables and their 
distributions in the data; these results are presented in Table 6.1. We also divided age at 
diabetes diagnosis into three categories: less than 40, between 40 and 60, and older than 
60 years. ESRD age and death age indicate age at ESRD diagnosis and death, 
respectively. Among the 90,429 diabetic subjects in the study, 8,254 (9%) of them were 
First Nations people. Among FN, 3,718 (45%) were male. Their mean age at diabetes 
diagnosis for FN was 47.2 (SD=±14) years. Among OSK, 44,820 (55%) were male. 
Their mean age at diabetes diagnosis was 61.6 (SD=±15.3) years. Of the total FN study 
population, 200 (2.4%) people developed ESRD, and 1,482 (18%) people died without 
the development of ESRD. Of the total OSK study population, 600 (0.7%) people 
developed ESRD, and 28,450 (34.6%) people died without developing ESRD. Mean 
ages were compared between FN and OSK using the t-test; the results show that the 
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mean ages at diabetes diagnosis (P<0.0001), at ESRD development (P<0.0001) and at 
death (P<0.0001) were significantly different between FN and OSK. There was a 
greater fraction of males among OSK compared with FN (P<0.0001). Compared with 
OSK, FN people experienced more cases of ESRD and fewer deaths (P <0.0001). 
Moreover, in the entire dataset, 48 patients were diagnosed with ESRD and diabetes in 
the same year. For such cases, we recoded the observation time from diabetes diagnosis 
to ESRD diagnosis as ranging from 0 to 0.5 year. There were 53,627 (59.3%) censoring 
events (loss to follow-up or end of study) in the study population during the whole 
study period. 
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Figure 6.1 Subjects in study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
108,037 members in the study 
cohort 
93,218 members with diabetes 
development equal to or later than 
1980 
(N=93,218)  
90,587 members with diabetes age 
equal to or larger than 20 years old 
and diabetes development equal to 
or later than 1980 (N=90,587) 
 
Exclude: Diabetes 
development before 1980 
(14,819) 
Exclude: Diabetes 
development before age 
20 (2,631)  
90,429 members with diabetes age 
equal to or larger than 20 years old, 
diabetes development equal to or later 
than 1980 and development of ESRD 
later than diabetes (N=90,429) 
Exclude: ESRD 
development before 
diabetes development 
(158) 
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Figure 6.2 ESRD cases by ethnicity. 
 
 
 
 
Exclude: Diabetes 
development before age 20 
Exclude: ESRD development 
before diabetes development   
 
Exclude: Diabetes 
development before 1980  
Total ESRD cases (N=1,396) 
ESRD cases among FN 
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ESRD cases among OSK 
(N=1,056) 
ESRD cases among FN 
(N=227) 
ESRD cases among FN 
(N=750) 
ESRD cases among FN 
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ESRD cases among FN 
(N=729) 
ESRD cases among FN 
(N=600) 
ESRD cases among FN 
(N=200) 
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Figure 6.3 Death cases by ethnicity. 
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 52 
 
Table 6.1. Baseline characteristics by ethnicity. 
Variable FN (N=8,254) 
Mean (±SD);  
N (%) 
OSK (N=82,175) 
Mean (±SD);  
N (%) 
P value 
 Male 3,718 (45.04%) 44,820 (54.5%)    P<0.0001 
Diabetes age 47.2 (±14) 61.6 (±15.3) P<0.0001 
Diabetes age 
<40 
40-60 
>60 
 
2,685 (32.5%) 
4,092 (49.6%) 
1,477 (17.9%) 
 
7,290 (8.9%) 
28,860 (35.1%) 
46,025 (56%) 
 
P<0.0001 
P<0.0001 
P<0.0001 
# of ESRD 200 (2.4%) 600 (0.7%) P<0.0001 
ESRD age 56.5 (±11.2) 64.1 (±13.7) P<0.0001 
# of Death 1,482 (18%) 28,450 (34.6%) P<0.0001 
Death age 66.4 (±14.4) 78.3 (±11.1) P<0.0001 
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6.2 Description of variables   
The variables, codes and values are described in Table 6.2. Age at diabetes diagnosis is 
treated as a continuous variable. 
 
Table 6.2. Description of variables. 
Variables  Description Codes/Values 
DIABAGE Age at diabetes diagnosis Years (Continuous) 
REGIND Registered Indian Status 0=never, 1=ever 
SEX Sex 0=male, 1=female 
TIME Time since diabetes diagnosis Years (Continuous) 
EVENT Types of events after diabetes development 
0=censoring, 
1=ESRD 
2=death without ESRD 
  
6.3 Non-parametric model 
6.3.1 Cause-specific hazard rates  
We can draw smoothed graphs of cause-specific hazard function for ESRD and 
death without ESRD from time of diabetes diagnosis. Figure 6.4 to Figure 6.6 present 
estimated smoothed hazard rate curves using the Epanechnikov kernel smoothed 
function. In these three graphs, bandwidth, abbreviated “bw”, is the optimal 
estimation from SAS software analysis.  Figure 6.4 presents the graph showing that 
the hazard rate for death was higher than that for ESRD, and we can also tell that hazard 
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rates increased over time (years since diabetes diagnosis) for both ESRD and death 
cases. Figure 6.5 presents crude smoothed hazard rates of ESRD over time between FN 
and OSK. The per-year risk of developing ESRD increased over time among FN and 
OSK. FN had a higher risk of ESRD than OSK. Figure 6.6 presents crude smoothed 
hazard rates of death over time between FN and OSK. The per-year risk of death 
increased over time among FN and OSK. For most of the study duration, the hazard rate 
of death was lower among FN than that of OSK.    
 
  
 
Figure 6.4 Overall hazard rates for ESRD and death cases. 
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Figure 6.5 Hazard rates of ESRD by ethnicity. 
 
 
Figure 6.6 Hazard rates of death without ESRD by ethnicity. 
6.3.2 Cumulative incidence function curves 
Figure 6.7 and Figure 6.8 present the CIF curves for ESRD cases and death without 
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ESRD cases for FN and OSK, respectively, and the p-values for the differences 
between these two groups were both less than 0.0001. Overall, FN had a higher 
probability of ESRD and lower probability of death than OSK over time (years since 
diabetes diagnosis). 
 
Figure 6.7 Cumulative incidence function (CIF) curve for ESRD by ethnicity. 
 
Figure 6.8 Cumulative incidence function (CIF) curve for death by ethnicity. 
 
6.4 Cox cause-specific model 
Applying the univariable Cox cause-specific hazard model for ESRD and death with 
ESRD showed that sex, age at diagnosis of diabetes and ethnicity were significant 
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predictors (p-values<0.0001). For the ESRD outcome, the univariable model showed 
that the risk of developing ESRD was 3.19 times higher for FN compared to OSK 
(Table 6.3). For the death outcome, the univariable model showed that the risk of death 
for FN was 0.50 times that for OSK (Table 6.4). 
Table 6.3. Univariable Cox cause-specific model for ESRD outcome. 
Variables β Hazard Ratios 95% CI* p-value 
Male 0.44 1.55 (1.34,1.79) <0.0001 
First Nation 1.16 3.19 (2.72,3.75) <0.0001 
Diabetes age -0.02 0.982 (0.977,0.986) <0.0001 
* CI: Confidence Interval 
Table 6.4. Univariable Cox cause-specific model for Death outcome. 
Variables β Hazard Ratios 95% CI* p-value 
Male 0.20 1.22 (1.19, 1.24) <0.0001 
FN -0.70 0.50 (0.47, 0.53) <0.0001 
Diabetes age 0.08 1.081 (1.080,1.082) <0.0001 
* CI: Confidence Interval 
After building multivariable models, we also tested the interactions between 
predictors in the model. The results show that for death without ESRD, there were 
significant interactions between ethnicity and age (P<0.0001) and between sex and age 
(P<0.0001) (Table 6.6), but no significant interaction for ESRD (Table 6.5). The final 
multivariable model showed that the risk of developing ESRD was 2.97 times higher 
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for FN compared to OSK (95% CI: 2.51-3.54, P<0.0001), adjusting for age at diabetes 
diagnosis and sex (Table 6.5). Most incident cases of diabetes occurred among FN in 
the age group of 40-49, while most new cases of diabetes occurred among OSK in the 
age group of 70+, leaving a nearly 25-year difference between FN and OSK in the age 
of diabetes diagnosis. The hazard ratios (HRs) of death without ESRD between FN 
males and OSK males with an age difference of 25 could be calculated as:  
HR = exp (1.19-25*0.07+0.0147*25) = 0.82 
This HR is less than 1, which means that the risk of death is lower. Moreover, death 
HRs between FN females and OSK females with an age difference of 25 could be 
calculated as follows: 
HR = exp (1.19-25*0.07+0.0147*25+0.0063*25) = 0.97 
 
Table 6.5. Multivariable Cox cause-specific model for ESRD outcome. 
Variables β Hazard Ratios 95% CI* p-value 
FN 1.09 2.97 (2.51,3.54) <0.0001 
Diabetes age -0.01 0.99 (0.985,0.995) <0.0001 
Male 0.49 1.64 (1.42,1.89) <0.0001 
* CI: Confidence Interval 
Table 6.6. Multivariable Cox cause-specific model for death outcome. 
Variables β Hazard Ratios 95% CI* p-value 
FN 1.19 3.30 (2.63,4.14) <0.0001 
Diabetes age 0.07 1.083 (1.081,1.083) <0.0001 
Male 0.82 2.27 (1.98,2.61) <0.0001 
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*CI: Confidence Interval 
6.5 Parametric proportional hazards model  
  Table 6.7 present AIC values (discussed in Section 5.2.4.3) for two parametric PH 
models for ESRD and  
 
Table 6.8 present AIC for two parametric PH models for death without ESRD 
respectively: the Weibull PH model and the exponential PH model. Model fitting is 
better if AIC values are lower. Therefore, the Weibull PH model was selected for both 
ESRD and death without ESRD. 
 
Table 6.7. AIC in Parametric PH models for ESRD. 
Parametric model  AIC  
Exponential   8,975 
Weibull   8,704 
 
 
Table 6.8. AIC in Parametric PH for death without ESRD. 
Parametric model AIC 
Exponential distribution 128,276 
Diabetes age*FN -0.0147 0.985 (0.982,0.989) <0.0001 
Diabetes age*Male  -0.0063 0.994 (0.992, 0.996) <0.0001 
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Weibull distribution 123,452 
 
 
Table 6.9 presents the results from the Weibull PH model for ESRD; we found 
similar hazard ratios (exp(1.07)=2.89), close to that from the Cox cause-specific hazard 
model between FN and OSK after adjusting for age and sex. For ESRD cases, the 
estimations of scale and intercept, σ and µ, were 0.60 and 4.66, respectively. The hazard 
function for the ith person, hi(t), from the Weibull PH model can be calculated from 
equation (5.7) to (5.10):  
0.66( ) 0.0004 1.66 exp( 0.01 1.07 0.48 )ih t t DIABAGE REGIND SEX      
Similarly, the hazard rate function for death without ESRD using the Weibull PH 
model results from *CI: Confidence Interval 
 
Table 6.10 is: 
0.41( ) 0.0001 1.41 exp(0.08 1.17 0.79
0.014 * 0.006 * )
ih t t DIABAGE REGIND SEX
REGIND DIABAGE SEX DIABAGE
   
 
 
Hazard rates can be estimated with covariate information. For example, the hazard 
rate of ESRD for 45-year-old FN females with diabetes is: 
h(t)=0.0004*1.66t
0.66
exp(-0.01*45+1.07-0.48)=0.0008t
0.66
 
with the hazard rate increasing over time. Moreover, the hazard rate of death without 
ESRD for 70-year-old FN females with diabetes is: 
h(t)=0.0001*1.41t
0.41
exp(0.08*70+1.17*1-0.79*1-0.014*70+0.006*70)=0.039 t
0.41
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with the hazard rate increasing over time. 
 
 
 
Table 6.9. Weibull PH model for ESRD. 
Variable β Hazard Ratios 95% CI* p-value 
Intercept  4.66    <0.0001 
Diabetes age  -0.01 0.99 (0.982, 0.992) <0.0001 
FN  1.07 2.91 (2.51, 3.36) <0.0001 
Male  0.48  1.62 (1.36, 1.94) <0.0001 
Scale     0.60     
Shape 1.66    
*CI: Confidence Interval 
 
Table 6.10. Weibull PH model for death without ESRD. 
Variable β HR 95% CI* p-value 
Intercept  6.40     <0.0001 
Diabetes age  0.08  1.08 (1.079, 1.082) <0.0001 
FN  1.17  3.22 (2.79, 3.71) <0.0001 
Male  0.79  2.20 (1.75, 2.76) <0.0001 
FN*Diabetes age  -0.014  0.986 (0.98, 0.99) <0.0001 
Male*Diabetes age   -0.006  0.994 (0.992, 0.996) <0.0001 
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Scale 0.71     
Shape 1.40     
*CI: Confidence Interval 
6.6 Piece-wise exponential proportional hazards model  
The piece-wise exponential distributions can be used to test the effect of covariates 
and also to estimate the hazard rates of events over time given the effects of other 
covariates. After fitting data to piece-wise exponential model, we found hazard rates 
increased overall and within each time interval, the rate was constant. Furthermore, in 
section 6.5, estimated hazard rates from Weibull PH model increased over time and in 
section 5.3, one assumption for SDM requires hazard rate being constant. The 
piece-wise exponential PH model incorporates the characteristics of the Weibull PH 
model prediction and the assumptions for SDM. 
We modeled the survival data with 3-year and 5-year intervals for ESRD (Table 
6.11 and Table 6.12 respectively). For ESRD cases, if we divided time into 5-year 
intervals, we find that the hazard rate increased with time monotonically. If we divided 
time into 3-year intervals, the hazard rate mostly increased over time monotonically, 
but there was a slight decrease in the 8
th
 time interval. For death cases, Table 6.14 
shows that with 5-year intervals, the hazard rate increased monotonically; for 3-year 
intervals (Table 6.13), the hazard rate usually increased monotonically, except that the 
hazard rate decreased slightly during the 2
nd
 interval and then increased throughout the 
following intervals. The hazard ratios between FN and OSK were close to the results 
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from the Cox cause-specific models for both ESRD and death without ESRD. For 
example, the hazard ratio of ESRD between FN and OSK was exp(1.09)=2.97 using 
3-year intervals or 5-year intervals, which was similar to the Cox cause-specific model 
results.   
The estimated hazard rate function of ESRD for the ith person, hi(t), from the 
piece-wise exponential PH model (3-year intervals) can be calculated from equations 
(5.15-5.16), j1, j2,…j8 are indicators for intervals. When j1 is equal to one and j2, 
j2, …, j8 are equal to zero, we could get hazard rate estimations for the second 
interval, the third year to the sixth year. 
   
 
i t exp 4.55 2.17j1 2.21j2 1.93j3 1.5j4 1.07j5 0.48j6 0.34j7 0.45j8 *
exp 0.01 1.09 0.49
h
DIABAGE REGIND SEX
         
  
 
Similarly, the estimated hazard rate of death without ESRD from the piece-wise 
exponential PH model (3-year intervals) for the ith person is: 
   
 
i t exp 6.71 1.75j1 1.76j2 1.47j3 1.16j4 0.86j5 0.59j6 0.30j7 0.06j8 *
exp 0.08 1.20 0.82 0.015 * 0.01 *
h
DIABAGE REGIND SEX REGIND DIABAGE SEX DIABAGE
         
   
Given the above two formulas, the hazard rates of ESRD for 45-year-old FN males 
with diabetes in the first and third time intervals (0-3rd, 6th-9th year) were 0.0023 and 
0.0029 respectively:
 
h(t)=exp(-4.55-2.17*1)*exp(-0.01*45+1.09*1-0.49*0)=0.0023 
h(t)=exp(-4.55-1.93*1)*exp(-0.01*45+1.09*1-0.49*0)=0.0029 
The hazard rates of death without ESRD for 45-year-old FN males with diabetes in the 
first and third time intervals (0-3rd, 6th-9th year) were 0.013 and 0.017 respectively: 
h(t)=exp(-6.71-1.75*1)*exp(0.08*45+1.2*1-0.82*0-0.015*1*45)=0.013 
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h(t)=exp(-6.71-1.47*1)*exp(0.08*45+1.2*1-0.82*0-0.015*1*45)=0.017  
 
 
 Table 6.11. Piece-wise exponential model for ESRD outcome with 3-year interval. 
    Variable 
         
β 95% CI* P-value 
Intercept 4.55 (3.55, 5.56) <.0001 
Male 0.49 (0.35, 0.64) <.0001 
FN 1.09 (0.92, 1.26)   <.0001 
Diabetes age -0.01         (-0.016,-0.006) <.0001 
j1 [3, 6) 2.17 (1.17, 3.16) <.0001 
j2 [6, 9) 2.21 (1.21, 3.21) <.0001 
j3 [9, 12) 1.93 (0.92, 2.93) 0.0002 
j4 [12, 15) 1.50 (0.50, 2.50) 0.0033 
j5 [15, 18) 1.07 (0.072, 2.07) 0.0356 
j6 [18, 21) 0.48 (-0.51, 1.48) 0.3435 
j7 [21, 24) 0.34 (-0.67, 1.34) 0.5106 
j8 [24, 25) 0.45 (-0.60, 1.50) 0.4037 
*CI: Confidence Interval 
 
 Table 6.12. Piece-wise exponential model for ESRD outcome with 5-year interval. 
Variable 
   
 β  95% CI* P-value 
Intercept   4.93 (4.56, 5.31) <.0001 
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Male   0.49  (0.35, 0.64) <.0001 
FN   1.09 (0.92, 1.26)   <.0001 
Diabetes age   -0.01    (-0.016, -0.006) <.0001 
j1 [5, 10)            1.83 (1.52, 2.15) <.0001 
j2 [10, 15)   1.53 (1.21, 1.85) <.0001 
j3 [15, 20)   0.81 (0.49, 1.12) <.0001 
j4 [20, 25)   0.05 (-0.26, 0.36) 0.7585 
*CI: Confidence Interval 
 
 Table 6.13. Piece-wise exponential model for death outcome with 3-year interval. 
Variable 
         
β 95% CI*    P-value 
Intercept  6.71  (6.38, 7.05)  <.0001 
Male  0.82  (0.68, 0.96) <.0001 
FN     1.20  (0.97, 1.43)   <.0001 
Diabetes age 0.08   (0.078, 0.081) <.0001 
Male*Diabetes age -0.006         (0.0043, 0.0082) <.0001 
FN*Diabetes age -0.015         (0.011, 0.019) <.0001 
j1 [3, 6) 
1.75   (1.43, 2.07) <.0001 
j2 [6, 9) 1.76  (1.44, 2.09) <.0001 
j3 [9, 12) 1.47  (1.15, 1.79) <.0001 
j4 [12, 15) 1.16   (0.84, 1.48) <.0001 
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j5 [15, 18) 0.86 (0.53, 1.18) <.0001 
j6 [18, 21) 0.59 (0.26, 0.91) 0.0004 
j7 [21, 24) 0.30  (-0.025, 0.63) 0.0702 
j8 [24, 25) 0.06  (-0.27, 0.40) 0.7152 
*CI: Confidence Interval 
 
 Table 6.14. Piece-wise exponential model for death outcome with 5-year interval. 
Variable 
         
β 95% CI*    P-value 
Intercept  6.83  (6.72, 6.94)  <.0001 
Male 0.82 (0.68, 0.96)  <.0001 
FN 1.19 (0.96, 1.42)    <.0001 
Diabetes age 0.08  (0.0777, 0.0804)  <.0001 
Male*Diabetes age  -0.01      (-0.0082, -0.0043)  <.0001 
FN*Diabetes age  -0.015       (- 0.018, -0.011)  <.0001 
j1 [5, 10)  1.62  (1.55, 1.70)  <.0001 
j2 [10, 15)  1.34  (1.26, 1.41)  <.0001 
j3 [15, 20)  0.84  (0.76, 0.91)  <.0001 
j4 [20, 25)  0.37 (0.29, 0.45)  <.0001 
*CI: Confidence Interval 
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6.7 Computational Modeling 
6.7.1 System Dynamics modeling 
FigureTable 6.9 presents one System Dynamics model with a 5-year interval, 
leaving 5 stocks that are labeled “diabetes 1”, “diabetes 2”, “diabetes 3”, “diabetes 4” 
and “diabetes 5”. Another two stocks presented in the model are called “ESRD” and 
“Death without ESRD”. Diabetes progression is represented by flows such as “diabetes 
progression 2”, “diabetes progression 3”, “diabetes progression 4” and “diabetes 
progression 5”. Diabetic people may develop ESRD or die without developing ESRD. 
Flows for ESRD development are shown in the model by “ESRD incidence 1” through 
“ESRD incidence 5”, and similarly, flows from diabetes to death without ESRD are 
indicated as “Death at diabetes interval 1” through “Death at diabetes interval 5”. 
The values of flows are ultimately determined by stock values and constant rate 
values. For example, in this model, ESRD incidence 1 flow is determined as the stock 
value of “diabetes 1” times the constant rate “ESRD rate 1”. In this model, we used a 
subgroup method to stratify the model by FN males, FN females, OSK males, and OSK 
females. The rates of ESRD and death were both subgrouped by ethnicity and sex. In 
our analysis, age at diabetes diagnosis was treated as a continuous variable, so we also 
used subgroups to present age at diabetes diagnosis categories from age 20 to age 107.  
The structure of the model also included competing risk effects of ESRD and death 
among the diabetic population. During each year of the study period, there were 
incident cases of diabetes coming into the model by entering the stock of “diabetes 1”. 
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Once people entered the “diabetes 1” stock, there were three stocks to which they could 
transfer: “ESRD”, “Death without ESRD” and “diabetes 2” (the last of which 
represented the second stock of the diabetic population). The mean time for people to 
move from stock “diabetes 1” to “diabetes 2” was 5 years. Again, for people who 
entered the diabetes 2 stock, they could go in three directions: ESRD, death without 
ESRD and “diabetes 3”. The same applied for people in the stock of “diabetes 3” or 
“diabetes 4”. Eventually, if people had diabetes for over 20 years, which means that 
they would enter the stock of “diabetes 5”, there were only 2 directions for them to go: 
“ESRD” and “Death without ESRD”. The 3-year interval model was similar to this 
5-year interval model but required 4 more stocks for diabetes, flows between stocks, 
ESRD rates from diabetes to ESRD, and death rates from diabetes to death.  
 
Figure 6.9 System Dynamics Model with a 5-year interval. 
 
To check the goodness of fit of our dynamic modeling predictions, we compared 
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the model prediction with historical data and drew graphs in EXCEL. Figure 6.10 
shows the comparison between historical data and model data for the ESRD event 
using 3-year piece-wise exponential estimations from survival analysis. In this figure, 
after around year 1996, there was a discrepancy between historical data and model 
data. A similar goodness of fit pattern is shown in Figure 6.11, which shows the 
comparison between historical data and model data for ESRD using 5-year piece-wise 
exponential PH survival analysis, and there was a certain discrepancy during the 
entire study period. Figure 6.12 and Figure 6.13 present a comparison between 
historical data and model data for death without ESRD. The 5-year interval model 
overestimated death incidence cases for most of the study duration, while 3-year 
interval estimations from the model showed that after year 1992 since diabetes 
diagnosis, the incident cases of deaths were underestimated by the model. 
 
Figure 6.10 Comparison of historical data with model-estimated data with a 3-year 
interval analysis of a piece-wise exponential model for ESRD. 
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Figure 6.11 Comparison of historical data with model-estimated data with a 5-year 
interval analysis of a piece-wise exponential model for ESRD. 
 
Figure 6.12 Comparison historical data with model estimated data with 3-year interval 
analysis of piece wise exponential for death without ESRD. 
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Figure 6.13 Comparison of historical data with model-estimated data with a 5-year 
interval analysis of a piece-wise exponential model for death without ESRD. 
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6.7.2 Agent-based modeling 
 
Figure 6.14 State chart of the agent-based model for person flow. 
 
Figure 6.14 presents one state chart of competing risks effects of ESRD and death 
without ESRD. There are 9 states for diabetes. For each diabetes state, there are two 
other states connected with it, that is, “ESRD” and “DeathWithoutESRD”. Links 
between states are transitions. ESRD and death here are also competing risk events, and 
those people who transition to the “ESRD” state cannot enter “DeathWithoutESRD” 
 73 
 
because death represents death without ESRD. Similarly, a person who transitions from 
diabetes to “DeathWithoutESRD” will not enter the “ESRD” state. Transitions from 
diabetes state to “ESRD” or from diabetes state to “DeathwithESRD” are the 
estimated hazard rates. Transitions between diabetes states are timeout such as 3 years 
or 5 years. There is a branch between state 5 and state 6, and this function is used to 
provide flexibility to support both 3-year and 5-year statecharts. Specifically, if the time 
for people to stay in one statechart is 5 years, the outward transition goes back to 
“diabetesPeriod5” (i.e., the person remains in “diabetesPeriod5”); otherwise, the 
diabetic person moves on to “diabetesPeriod6” and then progresses to later states (up to 
“diabetesPeriod9”).  
Figure 6.15 to Figure 6.18 compared historical data and model predictions from 
one simulation experiment, which matched well for both ESRD and death cases when 
we used ABM with either a 3-year or a 5-year interval. One point needs to be stated 
here. The historical ESRD case curve dropped near the end of the study. One possible 
reason for this is that the ESRD definition needs a 3-month duration for dialysis. In the 
data we had, the number of ESRD cases was underestimated for the year 2005.   
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Figure 6.15 Comparison between historical data and model-estimated data with a 
3-year interval analysis of a piece-wise exponential model for ESRD. 
 
 
Figure 6.16 Comparison between historical data and model-estimated data with a 
5-year interval analysis of a piece-wise exponential model for ESRD. 
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Figure 6.17 Comparison between historical data and model-estimated data with a 
3-year interval analysis of a piece-wise exponential model for death without ESRD. 
 
 
Figure 6.18 Comparison between historical data and model-estimated data with a 
5-year interval analysis of a piece-wise exponential model for death without ESRD. 
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To further analyze the data, we performed a subgroup analysis. Figure 6.19 to 
Figure 6.22 present comparisons of ESRD between the historical data and model 
predictions for FN males, FN females, OSK males, and OSK females, respectively. The 
results show that all of the data matched well. Similar results were found for death in 
these four groups (Figure 6.23 to Figure 6.26). 
 
Figure 6.19 Comparison between historical data and model-estimated data with a 
3-year interval analysis of a piece-wise exponential model for ESRD in FN males. 
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Figure 6.20 Comparison between historical data and model-estimated data with a 
3-year interval analysis of a piece-wise exponential model for ESRD in FN females. 
 
 
Figure 6.21 Comparison between historical data and model-estimated data with a 
3-year interval analysis of a piece-wise exponential model for ESRD in OSK males. 
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Figure 6.22 Comparison between historical data and model-estimated data with a 
3-year interval analysis of a piece-wise exponential model for ESRD in OSK females. 
   
 
Figure 6.23 Comparison between historical data and model-estimated data with a 
3-year interval analysis of a piece-wise exponential model for death without ESRD in 
FN males. 
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Figure 6.24 Comparison between historical data and model-estimated data with a 
3-year interval analysis of a piece-wise exponential model for death without ESRD in 
FN females. 
 
 
Figure 6.25 Comparison between historical data and model-estimated data with a 
3-year interval analysis of a piece-wise exponential model for death without ESRD in 
OSK males. 
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Figure 6.26 Comparison between historical data and model-estimated data with a 
3-year interval analysis of a piece-wise exponential for death without ESRD in OSK 
females. 
 
The above graphs are based on a single simulation realization of the agent-based 
model. We also performed Monte Carlo analysis based on the model with 100 
simulation realizations. Figure 6.27 and Figure 6.28 present comparisons between 
historical and model-predicted data for overall ESRD and death without ESRD incident 
cases using a 3-year interval piece-wise exponential PH model. The gray area 
represents agent-based dynamic model predication data (given 100 realizations), and 
the red line presents historical data. The darkest color indicates 2.5% simulation results 
and the 97.5% simulation results are marked with lightest grey area. The figures show 
good matches between these model data and historical data. Figure 6.29 to Figure 6.36 
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matches between historical data and model-predicted data. 
 
Figure 6.27 Comparison between incident historical data and model-estimated data 
for ESRD from a Monte Carlo model. 
 
 
Figure 6.28 Comparison between incident historical data and model-estimated data 
for death without ESRD from a Monte Carlo model. 
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Figure 6.29 Comparison between incident historical data and model-estimated data 
for ESRD in FN males from a Monte Carlo model. 
 
 
Figure 6.30 Comparison between incident historical data and model-estimated data 
for ESRD in FN females from a Monte Carlo model. 
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Figure 6.31 Comparison between incident historical data and model-estimated data 
for ESRD in OSK males from a Monte Carlo model. 
 
 
Figure 6.32 Comparison between incident historical data and model-estimated data 
for ESRD in OSK females from a Monte Carlo model. 
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Figure 6.33 Comparison between incident historical data and model-estimated data 
for death without ESRD in FN males from a Monte Carlo model. 
 
 
Figure 6.34 Comparison between incident historical data and model-estimated data 
for death without ESRD in FN females from a Monte Carlo model. 
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Figure 6.35 Comparison between incident historical data and model-estimated data 
for death without ESRD in OSK males from a Monte Carlo model. 
 
 
Figure 6.36 Comparison between incident historical data and model-estimated data 
for death without ESRD in OSK females from a Monte Carlo model. 
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Chapter 7 Discussion and conclusions 
7.1 Interpretation 
The results of this study will be discussed according to the study objectives: 
1. To increase our understanding of why there are disparities in ESRD rates between 
FN and OSK with diabetes. 
      a.  To determine whether there are significant disparities in the risk of ESRD 
development between FN and OSK. 
      b.  To determine whether there are significant disparities in the risk of 
mortality without ESRD between FN and OSK. 
First, the interpretation will start with the descriptive analysis. As observed in 
Figure 6.4, within the entire study cohort, the risk of death is higher than the risk of 
ESRD. FN people had higher hazard rates of ESRD compared with OSK over the 
whole study period (Figure 6.5). Figure 6.6 shows hazard rate curves for death without 
ESRD when not corrected for age of diabetes diagnosis, and among most of the study 
cohort, FN exhibited lower rates of death following diagnosis except after the 22nd 
year since diabetes diagnosis. To summarize, the risk of ESRD and the risk of death 
increase with time since diabetes diagnosis. FN had a higher risk of ESRD than OSK 
without adjusting for diabetes diagnosis age or sex; the crude risk of death without 
ESRD is lower among FN than that among OSK except near the end of study. Higher 
rates of death among OSK may play a role in the manifested lower rates of ESRD 
among OSK than FN. 
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Second, we will discuss the statistical modeling results. Cox cause-specific model 
analysis showed that FN people had about 3 times higher risk of ESRD than OSK 
people, after adjusting for diabetes diagnosis age and sex. Diabetes development at 
younger age increases the risk of ESRD. This may be because the long duration of 
diabetes leads to the accumulation of more damage to the kidneys (79). FN had lower 
risk of death than OSK before adjusting for age and sex difference. However, after 
adjusting for diabetes diagnosis age, sex, interaction between age and sex and 
interaction between age and ethnicity, FN had higher risk of death than OSK given the 
same sex and diabetes diagnosis age (younger than 81 years old). Moreover, most 
incident diabetes cases occur among FN in the 40-59 year age group, while most 
incident cases occur among OSK in the 70+ age group (23). From section 6.4, results 
from multivariable Cox cause-specific model for death without ESRD showed that 
after adjusting for 25-year age difference, FN had lower risk of death than OSK. Death 
as a competing risks event occurs more often among OSK, leading to the manifested 
situation that FN had higher rates of ESRD.   
Similarly, parametric models can give hazard ratios similar to those of Cox 
cause-specific PH models. Moreover, exact estimations of hazard rates can be obtained 
based on different distributions associated with the hazard function, such as the Weibull 
distribution and piece-wise exponential distribution. From the Weibull PH model, we 
found that hazard rates for both ESRD and death increase over time since diabetes was 
diagnosed.  
2. A lower risk of death without ESRD for FN than that for OSK has been shown in 
 88 
 
Saskatchewan (7). The statistical analysis shows that with or without adjustment 
for age and sex, death risk is lower for FN than for OSK when patients are at the 
pre-ESRD stage. Moreover, similar competing risks of ESRD and death without 
ESRD have been shown in a comparison between African-Americans and 
non-African-Americans (51). When compared with non-African-Americans, 
African Americans were reported to have a higher ESRD risk for all age group 
and CKD stages and a higher risk of death with ESRD except for those being old 
and with severe kidney disease. Among Pima Indians, diabetes onset at a young 
age has been associated with increased rates of ESRD among Pima Indians. 
Longer accumulation of damage to the kidney may increase the risk of ESRD (79). 
One study reported the conflicting findings that FN had a lower crude risk of 
death compared with non-FN, while after adjustment for age and sex, FN had a 
higher risk of death (8). 
3. To build Saskatchewan diabetic ESRD dynamic models. 
c. To estimate hazard rates for ESRD and mortality without ESRD and to build a 
dynamic model using hazard rate estimations. 
d. To validate models by comparing model-predicted data with historical data. 
We used a piece-wise exponential model and built a System Dynamics model and 
an agent-based model based on piece-wise exponential distributions with two different 
intervals. To our understanding, the 3-year interval would be more precise because the 
baseline hazard rates of the 6th, 7th, and 8th intervals
 
are different from the 9th interval. 
Here interval 6th indicates 15th year to 18th year since diabetes diagnosis. 
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As shown in Figure 6.31 to Figure 6.57, we found that there is a sizeable 
divergence between historical data and model-predicted data from the System 
Dynamics model but that the agent-based model matches the historic data quite closely, 
both in terms of point estimates and in terms of qualitative stochastic variability. The 
primary reason for this difference between SDM and ABM is that for the SDM, 3 years 
is the mean time for people to stay in the stock and then to transition to the next diabetes 
stock, and there might be some people who leave the stock quickly (without taking 3 
years) and also some people who stay in the stock for more than 3 years, which distorts 
the estimation. However, in ABM, we track one individual flowing from one diabetes 
state to another, and that person stays in one diabetes state for precisely 3 years, which 
gives a good estimation of incident cases of ESRD and death without ESRD. 
7.2 Limitations and strengths 
7.2.1 Limitations of the study population  
Selection bias 
      Selection bias is defined as “error due to systematic differences in characteristics 
between those who are selected for the study and those who are not” (80). One typical 
example of selection bias in a cohort study is loss to follow-up. Diabetes cases in this 
study were based on clinical diagnoses, which could have underestimated the 
frequency of diabetes. In addition, there might have been differences in screening and 
diagnosis strategies for people who have overt risk factors for diabetes, such as obesity, 
smoking, and high blood pressure, leading to differences in their inclusion in the 
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diabetic group. 
Misclassification bias 
     Misclassification bias, also called information bias, may “result from a systematic 
tendency for individuals selected for inclusion in the study to be erroneously placed in 
exposure or disease categories, thus leading to misclassification” (80). One type of 
misclassification bias comes from classification of races. We could only identify 
Aboriginal people as FN from the Indian Registry. Metis and non-registered Aboriginal 
people were included in the OSK group. This would tend to cause the current study to 
underestimate the real differences between FN and OSK in the risks of ESRD and death 
without ESRD. 
Confounding and other risk factors 
The relationship among exposure variables, confounding factors and outcome 
variables is shown below (80, 81): 
          
 
 
 
        
Figure 7.1 Confounding factor 
 
Confounder A is an independent risk factor for disease, and it is not a mediator 
between X and Y (81). Moreover, confounder A is also related to exposure X but is not 
a result of exposure X (81). In our study, controlling for confounding factors was 
Exposure X 
Confounder A 
Disease Y 
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limited. We controlled for age at diabetes diagnosis and sex in examing the differences 
in the risks of ESRD and death. This is a limited number of variables, which did not 
include several important risk factors for diabetes and ESRD. As mentioned in the 
literature review, risk factors for T2DM include obesity, physical inactivity, impaired 
glucose tolerance and GDM; for ESRD, risk factors include obesity, high blood 
pressure, GDM and poor glycemic control. Future research may need to explore other 
risk factors for both diabetes and ESRD and to compare the risks for ESRD and death 
without ESRD between groups. 
7.2.2 Strengths of the study population.  
      There are several advantages of the administrative dataset that we used, and some 
of them have been discussed in the literature (6, 23). First, the administrative database 
includes all of the covered population in Saskatchewan, which makes the study 
population a representative sample. Moreover, the sample size is large, which increases 
the study power. Surveys may underestimate the rates of diabetes based on their 
findings, suggesting that people tend to underreport diagnosed diabetes (80). Second, 
validated algorithms were used to define diabetes and ESRD. This increases the 
validity of the study. Third, the study period was 25 years, which is the longest, to our 
knowledge, in Canada. The long study period facilitates identifying cases of ESRD (6). 
All of the subjects in our study had diagnosed diabetes so that we could readily study 
diabetic ESRD among people who have diabetes.   
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7.3 Discussion of methodology.  
Descriptive analysis  
For the descriptive analysis component of this thesis, we used both CIF and hazard 
rate graphs for both ESRD and death cases. Both CIF and cause-specific hazard rate 
curves give information regarding the study population (82). Cause-specific hazard 
curves help provide information on the underlying etiological mechanisms of events 
(83) and show the estimated instantaneous rate of an event per unit time. CIF can be 
understood as the probability of specific events happening before a certain time among 
the whole population (82).  
Modeling analysis 
In this research, we used semi-parametric and parametric models to for the survival 
data. The Cox cause-specific model can be modeled in SAS, and this method has been 
used to understand competing risk effects of death on ESRD among patients who have 
CKD (84). Derose et al. (51) used the Fine & Gray method (85) and found similar 
competing risks effects of death on ESRD rates. Lim et al. (83) compared these two 
methods and suggested that when the rates of competing risk events are different, it 
would be applicable to use a Cox cause-specific model instead of the Fine & Gray 
model. Moreover, Lim et al. (83) mentioned that when analyzing competing risk events, 
it is still useful to present both methods and compare the results.  
Parametric models such as the Weibull PH model and piece-wise exponential PH 
model were tested to obtain exact estimates of hazard rates. The best-fitted Weibull 
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distribution model indicates that both hazard rates of ESRD and death increase over 
time. The Weibull PH model and piece-wise exponential PH model demonstrated that 
hazard ratios between groups are close to the hazard ratios from the Cox cause-specific 
model.  The bridge between competing risks survival analysis and competing risks 
dynamic modeling is the hazard rate. Hazard rates for SDM for a given phase of disease 
progression (as represented by a stock) must be constant throughout the time since they 
entered the stock so that the chance for one person to leave is independent of how long 
they have been in that stock. Therefore, we decided to use a piece-wise exponential 
distribution model to derive the appropriate hazard rates. The time interval division was 
arbitrary, and further research is required to identify the optimal time interval division.  
For the dynamic modeling investigation, we also compared ABM and SDM. 
Several comparisons can be discussed for these two methods of modeling (15, 66). First, 
for a large population and modest heterogeneity, ABM takes more time and 
computational memory than SDM. For example, 100 Monte Carlo simulations of the 
agent-based model took us almost half an hour, while an aggregate-model run took less 
than one minute. Moreover, more computer memory was required for ABM than that 
for the aggregate model. Second, if we double the size of the diabetes population, the 
increase of computational resources would increase at least linearly (66) in the 
agent-based model; by contrast, the performance of the System Dynamics model would 
remain the same. Although the ABM method takes more time and computational 
resources, there are several advantages to this method compared with aggregate 
modeling. First, in the aggregate model we used, subgroups represented population 
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characteristics, such as FN, OSK, males and females. We also used subgroups to 
represent diabetes diagnosis age (from 20 to 107 years). However, in ABM, capturing 
such heterogeneity can be performed with minimal performance cost and requires only 
adding parameters, such as REGIND, SEX and DIABAGE, to each agent (rather than 
imposing subscripting changes across the entire model), along with any associated 
logic. Second, while this thesis did not use this flexibility, an agent-based model 
permits using continuous hazard functions, such as the Weibull hazard function, instead 
of the memory-less assumption imposed by stocks in SDM. Third, in ABM (which 
incorporates stochastics), we are able to compare the degree of variability from the 
simulation results with those from the empirical data. 
Comparisons between model predictions and historical data (Figure 6.10 to Figure 
6.13) show that there are biases for both ESRD and death without ESRD. There are 
several possible reasons for these biases: 1) estimations from piece-wise exponential 
models may not be accurate enough; 2) chance may be playing a role and lead to bias; 3) 
the inexact time in transferring between stocks in the aggregate model could lead to 
some bias in the real transferring time. For example, in the 3-year interval model, some 
people may transfer quickly among stocks, and it may take them less than 3 years to go 
to the next stock, while others take longer than 3 years to go to the next stock. This may 
cause distortions in the historical data. We used ABM to test the third hypothesis, and 
the results gave considerably better matches for both ESRD and death without ESRD. 
In ABM, if we set up the time for one patient to progress to next diabetes state as 3 years, 
it is not mean time. Instead, it indicates that after exact 3 years, if the patient has not 
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developed ESRD or died, that patient will progress to diabetes.  
7.4 Conclusions 
First Nations people had a higher risk of ESRD before and after adjusting for age 
and sex. FN had lower risk of death than OSK before adjusting for age and sex 
difference. After adjusting for diabetes diagnosis age, sex, interaction between age and 
sex and interaction between age and ethnicity, FN had higher risk of death than OSK 
given the same sex and diabetes diagnosis age except for those people who got 
diagnosed of diabetes at the age of older than or equal to 81 years old. After adjusting 
for about 25-year difference in the age of diabetes diagnosis, FN had lower risk of 
death compared to OSK people. The much younger age of diabetes diagnosis among 
FN compared to OSK likely contributes to higher rates of ESRD because of a 
differential mortality effect since FN with diabetes are more likely to live long enough 
to develop ESRD. Moreover, using the same hazard rate estimations, ABM showed 
better matches between historical data and model-predicted data compared to SDM.  
7.5 Future work 
There are several possible avenues for future research on this topic. First, we may 
use the Fine and Gray model (85) to test the risk difference in ESRD or death without 
ESRD between FN and OSK or between males and females. We could compare the 
Fine and Gray model with the Cox cause-specific model. Although there are several 
macros in SAS to estimate CIF curves and test the difference between groups of CIFs, 
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for this task it would be convenient to use R software because there is an R package 
named “compsk” available to perform several such analyses. Second, we can use our 
agent-based model for diabetic ESRD and perform more tests, such as treating the 
hazard rates of death for FN and OSK the same in the model and testing whether there 
is any difference in ESRD rates between these two groups even with identical rates of 
death without ESRD. Additionally, we could include other factors, such as obesity, 
GDM, physical activity, dialysis, and treatment cost effects. Thirdly, more can be done 
in the piece-wise exponential model, such as dividing time into several intervals other 
than 3 years and 5 years. For example, we may divide the 25 years into six 3-year 
intervals and four 2-year intervals. Another possible future direction is to change the 
agent-based model using essentially continuous hazard functions, such as the Weibull 
hazard function.  
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